Amphastar Pharmaceuticals Inc buy klostergang
Summary
This prediction ended on 29.10.18 with a price of €16.78. The BUY prediction by klostergang finished with a performance of 18.25%. klostergang has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Amphastar Pharmaceuticals Inc | 1.081% | 1.081% | -33.083% | - |
iShares Core DAX® | -1.180% | 0.780% | 12.701% | 15.942% |
iShares Nasdaq 100 | -2.823% | -2.419% | 28.746% | 47.248% |
iShares Nikkei 225® | -3.908% | 1.574% | 11.146% | 8.676% |
iShares S&P 500 | -1.012% | -0.335% | 27.036% | 44.371% |
Comments by klostergang for this prediction
In the thread Amphastar Pharmaceuticals Inc diskutieren
klostergang stimmt dem Sentiment von 'Buy' zu
The Company currently has three abbreviated new drug applications, or ANDAs filed with the FDA, targeting products with a market size of over $0.5 billion, three biosimilar products in development targeting products with a market size of $15.0 billion, and 11 generic products in development targeting products with a market size of over $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2017. The Company's proprietary pipeline includes NDAs for Primatene
®
Mist and intranasal naloxone. The Company is currently developing several other proprietary products with various dosage forms.